Stereocomplexes for the delivery of anti-cancer agents
US-2024350644-A1 · Oct 24, 2024 · US
Benzodiazepine compounds with anti-flavivirus activity
US9168260B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9168260-B2 |
| Application number | US-201314380546-A |
| Country | US |
| Kind code | B2 |
| Filing date | Feb 22, 2013 |
| Priority date | Feb 24, 2012 |
| Publication date | Oct 27, 2015 |
| Grant date | Oct 27, 2015 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention describes a unique antiviral screen system. The assay is based on quantitatively monitoring viral activation of host cell beta-interferon (IFN-β) gene expression in a HEK293-derived reporter cell line expressing a firefly luciferase gene under the control of a human IFN-β promoter. Unlike the traditional high throughput antiviral assays that measure either the reduction of viral components/yields or cytopathic effect, the readout of the reporter assay in the present invention is the virus-induced host cellular innate immune response. Hence, the assay allows for identification of compounds that inhibit virus infection. In addition, because induction of IFN is one of the most common attributes of viruses, the assay is applicable to all the viruses that are able to infect the reporter cell line and induce IFN-β expression. Compounds that interfere with viral mediated activation of the interferon pathway in a primary screen, can be further screened with virus-specific assay to confirm their antiviral activity.
First claim
Opening claim text (preview).
We claim: 1. A method for treating a flavivirus infection, said method comprising administering to an infected subject an effective amount of at least one compound of the formula (I) or a pharmaceutically acceptable salt; wherein the flavivirus infection is dengue virus or yellow fever virus.
Assignees
Inventors
Classifications
Chemistry & Metallurgy · mapped topic
Physics · mapped topic
- A61K31/5513Primary
Human Necessities · mapped topic
Physics · mapped topic
Chemistry & Metallurgy · mapped topic
Patent family
Related publications grouped by family.
External sources
Next steps
Free tools are coming soon. Tell us what you want to track and we'll notify you.
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9168260B2 cover?
- The present invention describes a unique antiviral screen system. The assay is based on quantitatively monitoring viral activation of host cell beta-interferon (IFN-β) gene expression in a HEK293-derived reporter cell line expressing a firefly luciferase gene under the control of a human IFN-β promoter. Unlike the traditional high throughput antiviral assays that measure either the reduction of…
- Who is the assignee on this patent?
- Baruch S Blumberg Inst, Philadelphia Health & Educatio, Univ Drexel
- What technology area does this patent fall under?
- Primary CPC classification A61K31/5513. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Oct 27 2015 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).